… , we randomly assigned 4744 patients with New York Heart Association class II, III, or IV
heart failure and an ejection fraction of 40% or less to receive either dapagliflozin (at a dose of …

… patients with heart failure and a left ventricular ejection fraction of more than 40% to receive
dapagliflozin (… The primary outcome was a composite of worsening heart failure (which was …

… of mortality and heart failure hospitalization and improved symptoms in patients with heart
failure and reduced ejection fraction. We examined the effects of dapagliflozin according to …

… patients with heart failure and reduced ejection fraction (HFrEF) have chronic kidney disease
… We assessed the safety and efficacy of dapagliflozin in patients with HFrEF, according to …

… in risk of cardiovascular death or worsening heart failure when dapagliflozin was initiated
in patients with heart failure with reduced ejection fraction, with particularly large absolute risk …

… Patients with heart failure and preserved ejection fraction (HFpEF) have a high burden of …
patients with HFpEF (NCT03030235), we evaluated whether the SGLT2 inhibitor dapagliflozin …

… and safety of dapagliflozin in patients with HFimpEF. We hypothesized that patients with
HFimpEF would benefit from dapagliflozin to a similar extent as patients with LVEF consistently …

… in patients with heart failure and reduced ejection fraction. In this analysis, we examine
the effects of dapagliflozin on a … , using the Kansas City Cardiomyopathy Questionnaire (KCCQ). …

… of DAPA-HF that data from both dapagliflozin heart failure trials, DAPA-HF and DELIVER, will
… meta-analysis to assess the effect of dapagliflozin across the full spectrum of heart failure. …

… The cardiovascular (CV) benefits of dapagliflozin were first observed in the DECLARE-TIMI …
of dapagliflozin in patients with symptomatic heart failure with reduced ejection fraction in the …